In this video, Bruce Stark, MD, of Providence Saint Joseph Medical Center in Burbank, California, talks about the importance of choosing patients properly and screening for substance abuse disorders before prescribing or dispensing opioids.
With Americans’ use of opioids increasing, a panel from the National Institutes of Health set out to measure the drugs’ effectiveness in treating long-term chronic pain, and its report suggested that the risks outweigh the benefits.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.